VTGN · Company research
Vistagen Therapeutics, Inc. Common Stock (VTGN): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Dismissal without cause can qualify for severance at Vistagen (VTGN), even without a change in control. - Stock Titan | Dismissal without cause can qualify for severance at Vistagen (VTGN), even without a change in control. Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| VTGN Stock Price, Quote & Chart - ChartMill | VTGN Stock Price, Quote & Chart ChartMill | View source ↗ | ChartMill | Sep 30, 2026 | neutral | 0 | 0.6 |
| A Phase 3 trial missed its main goal overall, despite a possible nasal-spray benefit in very severe cases. - Stock Titan | A Phase 3 trial missed its main goal overall, despite a possible nasal-spray benefit in very severe cases. Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| Vistagen Reports $1.5 Million Revenue and $13.0 Million Quarterly Net Loss | VTGN Stock News - Quiver Quantitative | Vistagen Reports $1.5 Million Revenue and $13.0 Million Quarterly Net Loss | VTGN Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 14, 2026 | neutral | 0 | 0.6 |
| SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) - Yahoo Finance | SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) Yahoo Finance | View source ↗ | Yahoo Finance | Aug 4, 2026 | neutral | 0 | 0.6 |
| Vistagen adds board director with nearly three decades in neuroscience drug development - Stock Titan | Vistagen adds board director with nearly three decades in neuroscience drug development Stock Titan | View source ↗ | Stock Titan | Jul 31, 2026 | neutral | 0 | 0.6 |
| Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results? - Yahoo Finance | Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 15, 2026 | neutral | 0 | 0.6 |
| This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell - Stocktwits | This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell Stocktwits | View source ↗ | Stocktwits | Jun 30, 2026 | neutral | 0 | 0.6 |
| Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss - Benzinga | Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss Benzinga | View source ↗ | Benzinga | Jun 30, 2026 | neutral | 0 | 0.6 |
| Vistagen’s fasedienol fails main test, but one subgroup showed a signal - Stock Titan | Vistagen’s fasedienol fails main test, but one subgroup showed a signal Stock Titan | View source ↗ | Stock Titan | Jun 30, 2026 | neutral | 0 | 0.6 |
| This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell - TradingView | This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell TradingView | View source ↗ | TradingView | Jun 30, 2026 | neutral | 0 | 0.6 |
| VTGN Forecast — Price Target — Prediction for 2027 - TradingView | VTGN Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Here's Why Vistagen Therapeutics (NASDAQ:VTGN) Must Use Its Cash Wisely - Simply Wall Street | Here's Why Vistagen Therapeutics (NASDAQ:VTGN) Must Use Its Cash Wisely Simply Wall Street | View source ↗ | Simply Wall Street | Jun 17, 2026 | neutral | 0 | 0.6 |
| VISTAGEN THERAPEUTICS ($VTGN) Releases Q4 2026 Earnings - Quiver Quantitative | VISTAGEN THERAPEUTICS ($VTGN) Releases Q4 2026 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 15, 2026 | neutral | 0 | 0.6 |
| Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results? - Yahoo Finance | Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results? Yahoo Finance | View source ↗ | Yahoo Finance | May 19, 2026 | neutral | 0 | 0.6 |
| Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop - Schubert Jonckheer & Kolbe | Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop Schubert Jonckheer & Kolbe | View source ↗ | Schubert Jonckheer & Kolbe | Apr 27, 2026 | neutral | 0 | 0.6 |
| VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT - GlobeNewswire | VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT GlobeNewswire | View source ↗ | GlobeNewswire | Jan 16, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.